Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Perampanel (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- 23 Jan 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.
- 23 Jan 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2020.
- 30 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.